Discovery, Diagnostics and Management:
A new era for Dementia
KEYNOTE SPEAKERS AND PROGRAM TIMES
Dr Nicholas Ashton | Welcome and Keynote 1 Monday 4:30pm
Researcher, Department of Psychiatry and Neurochemistry, University of Gothenburg, SWEDEN
Dr. Ashton is an assistant professor of Neurochemistry at the Department of Psychiatry and Neurochemistry at the University Gothenburg in the group of Professor’s Henrik Zetterberg and Kaj Blennow. He also holds a senior researcher position at the department of Old Age Psychiatry, King’s College London, and Stavanger University in Norway. He received his PhD in 2017 from King’s College London in the group of Professor Sir Simon Lovestone. Dr. Ashton has more than a decade of experience in biofluid analysis and assay development for Alzheimer’s disease and related disorders, which ranges from discovery mass spectrometry methods to ultra-sensitive immunoassays. Recently this has produced ultra-sensitive single molecular array (Simoa) assays for phosphorylated tau in blood, which are now widely used in research settings, therapeutics trials and being validated for clinical use. His research now focuses on further assessing these tests in patient populations, preparing for widespread implementation. Further, he also now assessing different tau and synaptic forms in biofluids and how they may contribute to the knowledge of disease pathogenesis and ultimately clinical use.
He has published >200 original research articles in field of fluid biomarkers and in 2021, Dr. Ashton was awarded the Queen of Sweden Prize to a Young Alzheimer Researcher for his contribution dementia research. In addition, this year, he received the Viola Bergqvist award for mentorship.
Professor Christian Behl | Keynote 8 Wednesday 3:00pm
Director of the Institute of Pathobiochemistry, University Medical Center (UMC), Mainz, GERMANY
Christian Behl is Director of the Institute of Pathobiochemistry at the University Medical Center of the Johannes Gutenberg University Mainz, Germany, where he is also Full Professor and Chair. He received his PhD in Neurobiology from Julius-Maximilians-University Würzburg, Germany, worked as postdoctoral fellow on Alzheimer's Disease at The Salk Institute for Biological Studies La Jolla, California, and headed an Independent Research Group of the Max Planck Society at the MPI for Psychiatry in Munich. In Mainz, Behl translated his long-standing interest in neurodegenerative diseases into a research focus on autophagy, proteostasis, and oxidative stress in the context of age-related neurodegeneration. One of his continuing research goals is to uncover molecular maintenance and resilience processes that allow neurons to resist challenges that occur during neurodegeneration. More recently, he has been intensively reviewing Alzheimer's Disease research with the aim to develop a new understanding of its pathogenesis. Behl is member of a number of scientific boards, including the German Alzheimer Foundation.
Professor Maria Eriksdotter | Keynote 5 Wednesday 9:00am
Founder and the director of the Swedish national quality registry on cognitive/dementia disorders (SveDem), SWEDEN
Maria Eriksdotter, MD, PhD, is professor in geriatric medicine at Karolinska Institutet and senior consultant at Karolinska university hospital, Stockholm, Sweden. Since 2019 Dean of Karolinska Institutet Campus South and previously chair of the KI department of Neurobiology, care sciences and society.
Professor Eriksdotter is the founder and the director of the Swedish national quality registry on cognitive/dementia disorders (SveDem, www.svedem.se), one of the largest databases in the world on different dementia disorders, in which national quality indicators of diagnostics, treatment and dementia care can be followed.
Her research focus on treatment of Alzheimer´s disease and on comorbidities and dementia and has published >250 research articles. Prof Eriksdotter pioneered the first clinical trial in the world on implantation of encapsulated cells releasing nerve growth factor (NGF) directly to the forebrain in patients with Alzheimer´s disease. Using SveDem data, she has contributed to increased knowledge on the relationship between dementia and comorbidities with impact on everyday dementia care.
Professor Sharon Naismith | Keynote 7 Wednesday 2:10pm
MAPS, CCN NHMRC Leadership Fellow, Leonard P Ullmann Chair in Psychology, Brain and Mind Centre & Charles Perkins Centre, University of Sydney; Lead, Australian Dementia Network Memory Clinics Initiative.
Professor Sharon Naismith is a Clinical Neuropsychologist, National Health and Medical Research Council (NHMRC) Dementia Leadership Fellow and holds the Leonard P Ullman Chair in Psychology at the University of Sydney. Her work focuses on the mechanisms by which modifiable risk factors for dementia including depression, sleep disturbance, and cardiovascular disease impact on the brain and how best to treat them. She has authored more than 350 papers and has made new discoveries regarding key brain changes that underpin sleep disturbance and depression in older people. She leads the NHMRC ‘Centre of Research Excellence to Optimise Sleep in Brain Ageing and Neurodegeneration (CogSleep)', a new NHMRC ‘SIESTA’ Synergy Grant, focused on sleep and Alzheimer’s disease and the Australian Dementia Network Memory Clinics Initiative.
Professor Henry Brodaty AO MBBS, MD, DSc, FRACP, FRANZCP, FAHMS |
Keynote 4 Tuesday 4:40pm
Co-Director Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney, NSW
Henry Brodaty AO, MB BS, MD, DSc, FRACP, FRANZCP, FAHMS is a researcher, clinician, policy advisor and strong advocate for people with dementia and their carers. At UNSW Sydney, he is Scientia Professor and Montefiore Chair of Ageing and Mental Health, and Co-Director of the Centre for Healthy Brain Ageing. He has published extensively, is a senior psychogeriatrician at Prince of Wales Hospital, Sydney. He serves on multiple committees for the NSW and Australian governments and WHO.
He was previously President of International Psychogeriatric Association, Chairman of Alzheimer’s Disease International, and President of Alzheimer’s Australia NSW and Australia. In 2000 he became an Officer of the Order of Australia and in 2016 received the Ryman Prize for the world’s best development, advance or achievement that enhances quality of life for older people.
Associate Professor Michelle Lupton | Keynote 3 Tuesday 9:50am
QIMR Berghofer Medical Research Institute, Brisbane, QLD
Michelle Lupton specialises in Alzheimer’s disease genome-wide genetic association studies, neuroimaging genetics, genetic risk prediction, and Mendelian Randomisation analysis. She is currently an NHMRC Boosting Dementia Leadership Fellow based at QIMR Berghofer Medical Research Institute in Brisbane and was previously at Kings College London in the UK. Through her work with several Alzheimer’s disease cohort studies, she has contributed to world-class genetics consortia including the leading GWAS Meta-analyses and the Alzheimer’s Exome Sequencing Group which were the first to identify the TREM2 Alzheimer’s risk variant. She co-leads the PISA (Prospective Imaging Study of Aging) which focuses on prodromal and early stage Alzheimer’s disease, and leads the genetics, epidemiology and blood analysis streams. Her core research aims are to improve understanding of the effect of Alzheimer’s disease genetic risk factors, identify early disease and prodromal biomarkers and determine causal relationships between potential modifiable risk factors and Alzheimer’s disease.
Professor Peter Nestor | Keynote 6 Wednesday 9:50am
Professor in Neuroscience, Queensland Brain Institute, QLD
Peter Nestor is conjoint professor of cognitive neurology at the University of Queensland and the Mater Hospital, where he established the Memory and Cognitive Disorders Clinic in 2018. He trained in neurology in Melbourne and at the National Hospital for Neurology and Neurosurgery, Queen’s Square, London, in the 1990s and then did a PhD in cognitive neurology at the University of Cambridge. Afterwards he remained at the University of Cambridge/Addenbrooke’s Hospital for several years as a clinician-scientist. From 2012 until returning to Australia in 2017, he was Professor of Cognitive Neurology at the German Center for Neurodegenerative Diseases (DZNE). His research focuses on neuropsychology and brain imaging in neurodegenerative diseases that cause dementia.
His research publications have received over 18,000 citations with an H-Index of 69; his book contributions include chapters for the Oxford Text of Medicine; the Oxford Textbook of Cognitive Neurology and Dementia; and Dementia 5th Ed.
Dr Edwin Tan, BPharm (Hons), PhD | Keynote 9 Wednesday 3:50pm
Senior Lecturer, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney
Dr Edwin Tan is a Senior Lecturer School of Pharmacy, Faculty of Medicine and Health, The University of Sydney. He is also a registered pharmacist with clinical experience in both Australia and the UK. He was a previous NHMRC-ARC Dementia Research Development Fellow at the Karolinska Institute and Monash University. Dr Tan's research interests are in geriatric pharmacoepidemiology, particularly in improving the safe and effective use of medicines in people living with dementia.
Dr Tan has over 80 publications and has been awarded over $3.1M in competitive research funding. He is a member of the Australian Dementia Network (ADNeT) EMCR Accelerator Group and Chair of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Pharmacoepidemiology Special Interest Group. He is an executive editor for the British Journal of Clinical Pharmacology and has served on grant peer review panels for the NHMRC.
Dr Heather Snyder | Keynote 2 Tuesday 9:00am
Vice President, Medical & Scientific Relations, at the Alzheimer's Association and study team investigator for the development of the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), USA
Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer’s Association®. Dr. Snyder oversees the Association’s funding mechanisms; as the world’s largest nonprofit funder of Alzheimer's research, the Association is currently investing $310 million in more than 950 active best-of-field projects in 48 countries, including Australia. She is on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) and also serves on the study team for the Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), a tool that will collect longitudinal diagnostic and therapeutic clinical data, including measures of cognition, function and safety, from individuals treated with FDA-approved Alzheimer’s therapies in clinical settings nationwide. She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.
10 January 2023
10 February 2023
29 May 2023
29-31 May 2023